BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1645 related articles for article (PubMed ID: 29848298)

  • 1. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
    Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
    BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
    Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
    Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.
    Tang Y; Chen K; Luan X; Zhang J; Liu R; Zheng X; Xie S; Ke H; Zhang X; Chen W
    Int J Oncol; 2020 Dec; 57(6):1368-1380. PubMed ID: 33174013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.
    You ML; Chen YJ; Chong QY; Wu MM; Pandey V; Chen RM; Liu L; Ma L; Wu ZS; Zhu T; Lobie PE
    Oncotarget; 2017 Jun; 8(24):39323-39344. PubMed ID: 28445151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASPP2 suppresses stem cell-like characteristics and chemoresistance by inhibiting the Src/FAK/Snail axis in hepatocellular carcinoma.
    Xu L; Tong X; Zhang S; Yin F; Li X; Wei H; Li C; Guo Y; Zhao J
    Tumour Biol; 2016 Oct; 37(10):13669-13677. PubMed ID: 27473084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.
    Huan HB; Yang DP; Wen XD; Chen XJ; Zhang L; Wu LL; Bie P; Xia F
    J Exp Clin Cancer Res; 2017 Jun; 36(1):86. PubMed ID: 28646927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits.
    Zhao X; Zheng F; Li Y; Hao J; Tang Z; Tian C; Yang Q; Zhu T; Diao C; Zhang C; Chen M; Hu S; Guo P; Zhang L; Liao Y; Yu W; Chen M; Zou L; Guo W; Deng W
    Redox Biol; 2019 Jan; 20():427-441. PubMed ID: 30419422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
    Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
    Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tonicity-responsive enhancer-binding protein promotes stemness of liver cancer and cisplatin resistance.
    Lee JH; Suh JH; Kang HJ; Choi SY; Jung SW; Lee-Kwon W; Park SA; Kim H; Ye BJ; Yoo EJ; Jeong GW; Park NH; Kwon HM
    EBioMedicine; 2020 Aug; 58():102926. PubMed ID: 32739873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of stemness by miR-589-5p in hepatocellular carcinoma cells promotes chemoresistance via STAT3 signaling.
    Long J; Jiang C; Liu B; Dai Q; Hua R; Chen C; Zhang B; Li H
    Cancer Lett; 2018 Jun; 423():113-126. PubMed ID: 29196128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
    Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
    EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
    Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
    BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll like receptor 4 facilitates invasion and migration as a cancer stem cell marker in hepatocellular carcinoma.
    Liu WT; Jing YY; Yu GF; Han ZP; Yu DD; Fan QM; Ye F; Li R; Gao L; Zhao QD; Wu MC; Wei LX
    Cancer Lett; 2015 Mar; 358(2):136-143. PubMed ID: 25511737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
    Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
    Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LINC00680 enhances hepatocellular carcinoma stemness behavior and chemoresistance by sponging miR-568 to upregulate AKT3.
    Shu G; Su H; Wang Z; Lai S; Wang Y; Liu X; Dai L; Bi Y; Chen W; Huang W; Zhou Z; He S; Dai H; Tang B
    J Exp Clin Cancer Res; 2021 Jan; 40(1):45. PubMed ID: 33499874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tex10 is upregulated and promotes cancer stem cell properties and chemoresistance in hepatocellular carcinoma.
    Xiang X; Deng L; Xiong R; Xiao D; Chen Z; Yang F; Liu K; Feng G
    Cell Cycle; 2018; 17(11):1310-1318. PubMed ID: 30045663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of liver kinase B1 predicts poor prognosis in hepatocellular carcinoma.
    Tan X; Liao Z; Liang H; Chen X; Zhang B; Chu L
    Int J Oncol; 2018 Nov; 53(5):1913-1926. PubMed ID: 30226588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 83.